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Background: Upregulator of cell proliferation 4 (URG4) has been implicated in the oncogenesis of certain cancers.
However, the correlation between URG4 expression and clinicopathological significance in human cancer remains
unclear. Therefore, this study investigated its expression and clinicopathological significance in cervical cancer patients.
Methods: URG4 expression was examined using quantitative PCR (qPCR) and western blotting in normal cervical
epithelial cells, cervical cancer cells, and eight matched pairs of cervical cancer tissues and adjacent noncancerous
tissues from the same patient. In addition, immunohistochemistry (IHC) was used to examine URG4 expression in
paraffin-embedded tissues from 167 cervical cancer patients (FIGO stages Ib1-IIa2). Statistical analyses were performed
to evaluate associations between URG4 expression and prognostic and diagnostic factors.
Results: URG4 was significantly upregulated in the cervical cancer cell lines and tissues compared with the normal cells
and adjacent noncancerous cervical tissues. IHC revealed high URG4 expression in 59 out of the 167 (35.13%) cervical
cancer specimens. Its expression was significantly correlated with clinical stage (P < 0.0001), tumour size (P = 0.012),
T classification (P = 0.023), lymph node metastasis (P = 0.001) and vaginal involvement (P = 0.002). Patients with
high URG4 expression, particularly those who received concurrent chemotherapy and radiotherapy (P < 0.0001),
showed a shorter overall survival (OS) and disease-free survival (DFS) compared to those with the low expression of this
protein. Multivariate analysis revealed that URG4 expression is an independent prognostic factor for cervical cancer
patients.
Conclusions: Our results demonstrated that elevated URG4 protein expression is associated with a poor outcome
in patients with early-stage cervical cancer. URG4 may be a novel prognostic marker and therapeutic target for the
treatment of cervical cancer.
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Cervical cancer is the third most commonly diagnosed
gynaecological cancer and the fourth leading cause of
gynaecological cancer deaths worldwide, and it accounted
for 9% (529,800) of the total new cancer cases and 8%
(275,100) of the total cancer deaths among females in
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unless otherwise stated.in developing countries, including China [1]. In China,
there are approximately 130,000 new cases and 50,000
deaths due to cervical cancer per year [2]. Although the
incidence and mortality of cervical cancer have shown
downward trends, it is still the major cause of gynaecologic
oncology-related death in developing countries, and it is a
public health problem worldwide [1]. The treatment strat-
egy for cervical cancer depends on the clinical stage, which
is defined by the International Federation of Gynaecology
and Obstetrics (FIGO) staging system. There are several
traditional clinical variables that play important roles in
the FIGO staging system and patient prognosis, including
lymph node metastasis, tumour size and parametrialLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Zhang et al. BMC Cancer 2014, 14:885 Page 2 of 11
http://www.biomedcentral.com/1471-2407/14/885involvement [3,4]. After surgery, patients with one or
more of the abovementioned clinical variables require
supplementary therapy. However, traditional pathological
variables are not sufficiently reliable for predicting clinical
outcomes or for guiding optimal treatment strategies.
Many genes, such as annexin A2, Sam68 and HDAC10
[5-7], have been reported to be potentially useful prog-
nostic markers in cervical cancer, but there is still an urgent
need for additional research to identify novel biomarkers to
supply practical information for patient prognosis and
suitable therapeutic options.
Upregulated gene 4 (URG4) has been identified as an
oncogene with a full-length mRNA of 3.607 kb that en-
codes a protein of approximately 104 kDa in size. This gene
may be associated with the onset of oncogenesis and
cell cycle regulation [8-10]. URG4 was initially identified
using subtractive hybridisation in hepatocellular carcinoma
(HCC) cells [8]. Previous research on HCC and gastric
cancer evaluating tissue culture and tumour formation
in nude mice has demonstrated that URG4 promotes
HepG2 and GES-1 cell growth and that it is associated
with poor survival. In addition, elevated URG4 expression
in HCC and gastric cancer cells leads to upregulation of
cyclin D1, whereas low URG4 expression downregulates
the expression of this gene. A study by Chan Xie has indi-
cated that URG4 regulates cyclin D1 expression via the
Akt/FOXO3 signalling pathway by mediating its prolifera-
tive effects on HCC cells [10]. In addition, some studies
have shown that the URG4 expression is increased in
different types of cancers [11-13]. However, the clinical
significance of this gene in human cervical cancer remains
unknown.
In the present study, we demonstrated that the expres-
sion of URG4 is upregulated in cervical cancer cells and
surgical specimens. Moreover, its expression in cervical
cancer is associated with clinical stage, tumour size, T
classification, N classification and vaginal involvement.
Multivariate analysis revealed that URG4 may be an inde-
pendent biomarker for predicting cervical cancer prognosis.
More importantly, its upregulation is indicative of a poor
prognosis, particularly in patients receiving concurrent
chemotherapy and radiotherapy. Our results suggest that
URG4 may be an independent biomarker for prognosis
and that it represents a therapeutic target for the treat-
ment of cervical cancer.
Methods
Cell lines
A primary culture of normal cervical epithelial cells was
established from a biopsy of noncancerous cervical epi-
thelium and was cultured in complete KeratinocyteSFM
medium (Invitrogen, Carlsbad, CA, USA). Patient consent
was obtained prior to the use of the clinical materials for
research purposes, and the patient consent and protocolwere approved by Sun Yat-sen University Cancer Center
Institutional Review Board. Eight human cervical cancer
cell lines were purchased from the American Type Culture
Collection (HeLa, HeLa 229, C-33A, MS751, SiHa and Ca
Ski) and the Cell Bank of Type Culture Collection of the
Chinese Academy of Sciences (HCC 94 and ME-180). The
HeLa, HeLa 229, C-33A, MS751 and SiHa cells were
cultured in Eagle’s minimum essential medium (Gibco BRL,
Rockville, MD). The Ca Ski and HCC 94 cells were cultured
in RPMI-1640 medium (Gibco BRL, Rockville, MD), and
the ME-180 cells were cultured in McCoy’s 5A medium
(Sigma) supplemented with 10% foetal bovine serum (FBS)
(HyClone, Logan, UT, USA).
Samples and clinical characteristics
This study was conducted on a total of 167 paraffin-
embedded cervical cancer samples, which were histo-
pathologically and clinically diagnosed at the Sun Yat-Sen
University Cancer Centre between 1999 and 2005. The
clinical and clinicopathological classifications and staging
were determined according to the 2009 FIGO criteria. All
of the patients enrolled in this study were only found to
possess gynaecological tumour(s), and they were treated
without preoperative radiotherapy, chemotherapy, or
hormonal therapy. Patient consent was obtained prior to
the use of the clinical materials for research purposes, and
the patient consent and protocol were approved by Sun
Yat-sen University Cancer Center Institutional Review
Board. Clinical information pertaining to the samples is
summarised in Table 1. The follow-up time for the primary
cervical cancer cohort ranged from 0.8 to 187 months, and
the median follow-up time was 64.06 months. The per-
centage of tumour purity in the sections adjacent to the
tumours and the normal cervical tissues used for RNA
extraction were estimated during routine histopatho-
logical analyses.
qPCR
Total RNA samples from the cell lines and primary tumour
materials were extracted using TRIzol reagent (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s in-
structions. The extracted RNA was pretreated with RNase-
free DNase, and 2 μg of RNA was used for cDNA synthesis
using random hexamers. The URG4 sense primer was
5′-CGCAATCATCTCCTTCCATT-3′, and the antisense
primer was 5′-GATTTGGGAGAAGTAGCCCC-3′. For
the glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
gene, the sense primer 5′-AATGAAGGGGTCATTGAT
GG-3′ and the antisense primer 5′-AAGGTGAAGGTC
GGAGTCAA-3′ were used. The initial PCR was performed
as follows: denaturation at 95°C for 10 min, followed by
44 cycles of denaturation at 95°C for 15 s, primer annealing
at 60°C for 60 min, and a primer extension step at 65°C for
5 s. Upon the completion of these steps, a final extension at
Table 1 Clinicopathological characteristics and URG4
expression in the cervical cancer patients
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at 4°C. qPCR was then conducted to determine the fold
increase of URG4 mRNA in each of the primary cervical
tumours relative to paired adjacent noncancerous tissue
taken from the same patient. The primers were de-
signed using Primer Express v2.0 (Applied Biosystems).
The expression data were normalised to the geometric
mean of GAPDH expression to control for variability in
expression levels, and all of the experiments were
performed in triplicate.
Western blotting
Cells at 70% to 80% confluence were washed twice with
ice-cold phosphate-buffered saline (PBS) and lysed on
ice in radioimmunoprecipitation assay buffer (RIPA; Cell
Signaling Technology, Danvers, MA) containing complete
protease inhibitor cocktail (Roche Applied Sciences,
Mannheim, Germany). Fresh tissue samples were ground
to powder in liquid nitrogen and lysed using SDS-PAGE
sample buffer. Equal concentrations of each protein sam-
ple (20 μg) were separated on 6% SDS polyacrylamide gels
and transferred to polyvinylidene fluoride (PVDF) mem-
branes (Immobilon P, Millipore, Bedford, MA). The mem-
branes were blocked with 5% fat-free milk in Tris-buffered
saline containing 0.1% Tween-20 (TBST) for 1 h at room
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anti-upregulator of cell proliferation 4 antibody (1:1000,
Sigma, HPA020134) overnight at 4°C. URG4 expression
was determined using a horseradish peroxidase-conjugated
anti-rabbit IgG antibody (1:3000, Santa Cruz, SC-2004)
and enhanced chemiluminescence (Pierce) according
to the manufacturer’s protocols. The membranes were
probed with anti-α-tubulin mouse monoclonal antibody
(1:1000, Sigma, T5168) as a loading control.
Immunohistochemical analysis
Immunohistochemical analysis was performed to assess
alterations in protein expression in the 167 human cer-
vical cancer tissues. Briefly, paraffin-embedded specimens
were cut into 4-μm thick sections and baked at 65°C for
30 min. The sections were deparaffinised with xylenes and
rehydrated. They were then submerged into EDTA anti-
genic retrieval buffer and microwaved for antigenic re-
trieval. Next, they were treated with 3% hydrogen peroxide
in methanol to quench endogenous peroxidase activity,
followed by incubation with 1% bovine serum albumin to
block any nonspecific binding. The sections were then
incubated with an anti-URG4 rabbit polyclonal antibody
(1:150, Sigma, HPA020134) overnight at 4°C. Normal goat
serum was used as a negative control. After washing withFigure 1 Overexpression of URG4 mRNA and protein in cervical cance
cervical cancer cell lines (HeLa, HeLa 229, HCC 94, C33a, Ca Ski, MS751, ME-
blotting (a) and qPCR (b). The expression levels were normalised against α
deviation of the mean (SD), which was calculated from three parallel experPBST, the tissue sections were incubated with a biotinyl-
ated anti-rabbit secondary antibody (Sigma), followed by
further incubation with streptavidin-horseradish peroxid-
ase complex (Sigma). The tissue sections were immersed
in 3-amino-9-ethylcarbazole, counterstained with 10%
Mayer’s haematoxylin, dehydrated and mounted in Crystal
Mount.
The degree of immunostaining of the formalin-fixed,
paraffin-embedded sections was evaluated independently
by two observers who were blinded to the histopatho-
logical features of the samples and the patient data. The
scores assigned by the two independent investigators were
averaged, and they were based on both the proportion of
positively stained tumour cells and the intensity of stain-
ing. The proportion of tumour cells was scored as follows:
1 (<10% positive tumour cells), 2 (10-50% positive tumour
cells), 3 (50-75% positive tumour cells), and 4 (>75%
positive tumour cells). Staining intensity was graded ac-
cording to the following criteria: 0 (no staining); 1 (weak
staining = light yellow), 2 (moderate staining = yellow
brown), and 3 (strong staining = brown). The staining
index was calculated as the product of the proportion
of positive cells and the staining intensity score. Using
this method of assessment, we evaluated URG4 expression
in cervical cancer cells via a staining index (scored as 0, 1,r cell lines. (a and b) Expression levels of URG4 mRNA and protein in
180 and SiHa) and normal cervical cell lines were examined via western
-tubulin and GAPDH, respectively. The error bars represent the standard
iments. *P < 0.01.
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sion were chosen based on a measure of heterogeneity
using the log-rank test with respect to overall survival
(OS). The optimal cut-off values were assigned as follows:
staining scores of ≥6 described tumours with high URG4
expression, and scores of ≤4 were assigned to those with
low URG4 expression.
Statistical analysis
The OS rate was the primary endpoint of this study, and
the secondary endpoint was the disease-free survival
(DFS) of the cervical cancer patients. OS was defined asFigure 2 Overexpression of URG4 mRNA and protein in cervical cance
URG4 protein expression in eight matched pairs of cervical cancer tissues (
loading control. (b) The average T/ANT ratios of URG4 mRNA expression in th
quantified using qPCR and normalised against GAPDH. The error bars represe
three parallel experiments. (c) Immunohistochemical analysis of URG4 protein
**P < 0.01.the duration from the date of each patient’s hospitalisa-
tion to the date of death from any cause or to the cen-
soring of the patient at the date of the last follow-up.
DFS was defined as the time from hospitalisation to
local, regional, or distant treatment failure, other second
primary cancer, or death without evidence of a cervical or
second primary cancer.
All statistical analyses were conducted using SPSS 11.0
statistical software. The relationships between URG4 ex-
pression and the clinicopathological characteristics were
analysed using the chi-square test and Fisher’s exact test.
Bivariate correlations between the study variables werer tissues. (a) Representative images of western blotting analyses of
T) and adjacent noncancerous tissues (ANT). α-Tubulin was used as the
e paired cervical cancer (T) and adjacent noncancerous tissues (ANT) were
nt the standard deviation of the mean (SD), which was calculated from
expression in eight pairs of matched cervical cancer tissues. *P < 0.05.
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Survival curves were plotted using the Kaplan-Meier
method and were compared using the log-rank test. The
clinicopathological characteristics, which are used exten-
sively to predict prognosis in clinical practice, were eval-
uated using univariate and multivariate analysis with the
forward Cox regression model. In all cases, a P-value
of <0.05 was considered to be statistically significant.Results
URG4 is overexpressed in cervical cancer cell lines
To evaluate URG4 protein and mRNA expression in cer-
vical cancer cell lines, we used western blotting and qPCR,
and eight cervical cancer cell lines were assessed (HeLa,
HeLa 229, HCC 94, C-33A, Ca Ski, MS751, ME-180 and
SiHa) and compared with a normal cervical epithelial cell
line (N). The URG4 protein was highly expressed in the
cervical cancer cell lines and only weakly expressed in N
(Figure 1a). URG4 mRNA expression was at least 4.5-fold
greater in the cervical cancer cell lines compared to N
(Figure 1b).Figure 3 Expression of the URG4 protein in cervical cancer tissues fro
from immunohistochemical analyses of URG4 expression in normal cervica
statistical analyses of the average mean optical density (MOD) of URG4 stai
different clinical stages. (c) The statistical analyses of the average MOD of U
node metastasis-free group. *P < 0.05.URG4 is overexpressed in cervical cancer tissues
To determine whether URG4 is also highly expressed in
human cervical cancer clinical samples, we performed
qPCR and western blotting analyses on eight cervical
tumour samples (T) that were matched with adjacent
noncancerous tissue samples (ANT). As illustrated in
Figure 2b, URG4 mRNA expression increased by 8.4-
to 26.4-fold in all cervical cancer tissues compared to
the matched adjacent noncancerous tissues. Consistent
with these data, the URG4 protein was also upregulated in
the cervical cancer tissues compared to the surrounding
non-tumour regions (Figure 2b).
URG4 overexpression is associated with clinical features
of cervical cancer
We investigated URG4 expression in 167 paraffin-
embedded archived cervical cancer tissues using im-
munohistochemical staining. The samples included 68
stage Ib1 tumours, 59 stage Ib2 tumours, 38 stage IIa1
tumours and two stage IIa2 tumours. Among the 167
samples, high levels of URG4 protein expression were
detected in 59 (35.5%), and weak or no staining wasm patients at different clinical stages. (a) Representative images
l tissues and cervical cancer tissues at different clinical stages. (b) The
ning in normal cervical tissues and cervical cancer specimens at
RG4 staining in the lymph node metastasis group and the lymph






test P-valueLow expression High expression
(%) (%)
Age (y) ≥42 93 56 (60.2) 37 (39.8) 0.798 0.873
<42 74 46 (62.2) 28 (37.8)
Clinical stage Ib1 68 57 (83.8) 11 (16.2) 0.000 0.000
Ib2 59 32 (54.2) 27 (45.8)
IIa1 38 19 (50.0) 19 (50.0)
IIa2 2 0 (0.0) 2 (100.0)
T classification T1b1 113 74 (65.5) 39 (34.5) 0.005 0.003
T1b2 39 26 (66.7) 13 (33.3)
T2a 9 1 (11.1) 8 (88.9)
T2b 4 1 (25.0) 3 (75.0)
T4 2 0 (0.0) 2 (100.0)
N classification N0 140 91 (65.0) 49 (35.0) 0.001 0.002
N1 27 11 (40.7) 16 (59.3)
M classification Yes 7 4 (57.1) 3 (42.9) 0.827 1.000
No 160 98 (61.2) 62 (38.8)
Histological differentiation Well 8 7 (87.5) 1 (12.5) 0.058 0.069
Moderate 66 34 (51.5) 32 (48.5)
Poor 93 61 (65.6) 32 (34.0)
Expression of SCC ≤1.5 97 64 (66.0) 33 (34.0) 0.289 0.291
>1.5 51 27 (52.9) 22 (47.1)
None 19 11 (57.9) 7 (42.1)
Tumour size, cm <4 106 76 (71.7) 30 (28.3) 0.012 0.018
≥4 61 32 (52.5) 29 (47.5)
Histological type Squamous cell carcinoma 153 92 (60.1) 61 (39.9) 0.407 0.569
Adeno cell carcinoma 14 10 (71.4) 4 (28.6)
Deep stromal invasion Yes 100 55 (55.0) 45 (45.0) 0.123 0.139
No 67 47 (70.1) 20 (29.9)
Lymphovascular space involvement Yes 7 3 (42.9) 4 (57.1) 0.312 0.433
No 160 99 (61.9) 61 (38.1)
Positive parametrium Yes 5 2 (40.0) 3 (60.0) 0.326 0.378
No 162 100 (61.7) 62 (38.3)
Vaginal involvement Yes 10 1 (10.0) 9 (90.0) 0.002 0.004
No 157 101 (64.3) 56 (35.7)
Positive surgical margin Yes 3 1 (33.3) 2 (66.7) 0.320 0.561
No 164 101 (61.6) 63 (38.4)
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positive rate increased with increasing FIGO stage as
follows: 16.2% for Ib1 (11/68), 45.8% for Ib2 (27/59),
50% for IIa1 (19/38) and 100% for IIa2 (2/2). URG4 was
primarily localised to the plasma membrane (Figure 2).
Furthermore, IHC staining showed that URG4 expression
in the cervical cancer increased with increasing clinicalstage (Figure 3a). Quantitative IHC analysis revealed that
the mean optical density (MOD) values of URG4 staining
in all of the cervical cancer samples were higher than
those in the normal control cervical tissues. In addition,
the MOD values of URG4 staining significantly increased
with progression from stage Ib1 to IIa2 (P < 0.0001,
Figure 3b). Taken together, these observations indicate
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the clinical development of early-stage cervical cancer.
We further analysed the correlation between URG4
expression and the clinicopathological characteristics of
the patients (Table 1). As summarised in Table 2, there
were no significant correlations between URG4 protein
expression and patient age, M classification, histological
differentiation, SCC expression, histological type, deep
stromal invasion, lymphovascular space involvement, posi-
tive parametrium or positive surgical margin in the patients
with cervical cancer. However, URG4 expression was mark-
edly associated with clinical stage (P < 0.001), T classifica-
tion (P = 0.003), tumour size (P = 0.012), N classification
(P = 0.001) and vaginal involvement (P = 0.004). These
data were further confirmed by Spearman’s correlation
analysis. As shown in Table 3, the correlations between
URG4 expression and clinical stage, T classification, N
classification and vaginal involvement were 0.327 (P <
0.0001), 0.250 (P = 0.001), 0.254 (P = 0.001) and 0.236
(P = 0.002), respectively. Moreover, the MOD values of
URG4 staining were markedly higher in the lymph node
metastasis group than in the lymph node metastasis-
free group (P < 0.001, Figure 3c).
Taken together, the expression of the URG4 protein is
positively correlated with clinical stage, tumour size, T
classification, N classification and vaginal involvement.
Association between URG4 expression and patient
survival
Patient survival analysis showed a clear negative correl-
ation between URG4 protein expression and both the
OS and DFS of cervical cancer patients (both P < 0.0001,
Figure 4a, b). The cumulative OS and DFS rates for the
patients with high levels of URG4 expression were 52.5%
and 55.9%, respectively, whereas the rates were 97.1% and
89.8%, respectively, for the patients with low or no URG4
expression. Moreover, we analysed the prognostic value of
URG4 expression in select patient subgroups that were
stratified according to clinical stage, N classification, con-
current chemotherapy and radiotherapy and radiotherapy
(RT). Patients with tumours exhibiting high URG4 expres-
sion had a significantly shorter OS compared to those with
low-URG4-expressing tumours in the Ib1-Ib2 subgroupTable 3 Spearman correlation analysis of URG4 versus
clinicopathological factors
Variables URG4 expression level
Spearman correlation p-Value
Clinical staging 0.327 <0.000
T classification 0.250 0.001
N classification 0.254 0.001
Vaginal involvement 0.236 0.002
Tumour size 0.218 0.005(log-rank test, P < 0.0001, Figure 4c), in those without
lymph node metastasis (log-rank test, P < 0.0001, Figure 4d)
and in those receiving concurrent chemotherapy and
radiotherapy (log-rank test, P < 0.0001, Figure 4e). This
was not the case for the IIa1-IIa2 subgroup (log-rank test,
P = 0.485, Additional file 1: Figure S1a), the lymph node
metastasis group (log-rank test, P = 0.280, Additional
file 1: Figure S1b) or the radiotherapy group (log-rank test,
P = 0.06, Figure 4f).
In addition, Cox regression analysis revealed that URG4
expression and deep stromal invasion were independent
prognostic factors for poor OS in the cervical cancer
patients (Table 4).
Discussion
This is the first study to describe the association of
URG4 upregulation with poor prognosis in early-stage
cervical cancer patients. More importantly, high URG4
expression reduced the OS and DFS of these patients,
particularly those who received concurrent chemotherapy
and radiotherapy. Considering these findings, we suggest
that URG4 is a potential novel marker for prognosis and
represents a therapeutic target for the treatment of cervical
cancer patients.
Clinical evidence has indicated that URG4 is elevated
in patients with certain types of cancer. Its expression has
been shown to be associated with tumour aggressiveness
in osteosarcomas, prostate cancer and neuroblastomas
[11-13]. These findings suggest that URG4 may play an
important role in cancer development and progression.
Therefore, we assessed whether it is also clinically asso-
ciated with the development and progression of cervical
cancer. We found that the URG4 mRNA and protein
were highly expressed in cervical cancer cell lines and
cervical cancer samples (Ib-IIa). We further analysed the
relationships between URG4 expression and the clinical
characteristics of patients with early-stage cervical cancer.
There was a significant correlation between URG4 expres-
sion and clinical stage, T classification, tumour size, N
classification and vaginal involvement, strongly supporting
the hypothesis that this protein plays a role in the progres-
sion of cervical cancer and may represent a biomarker for
the identification of subsets of cervical cancer patients
with a more aggressive form of the disease. Univariate
and multivariate analyses showed that high URG4 expres-
sion is a predictor of poor prognosis in these patients.
Moreover, those with elevated expression showed a 52.5%
cumulative OS rate, which was significantly lower than
that in the patients with low expression levels (97.1%).
Furthermore, the patients (Ib1-Ib2) with high URG4
expression levels had poor outcomes. These findings
indicate that elevations in URG4 expression may be
predictive of a poor prognosis and short survival time
for early-stage cervical cancer patients.
Figure 4 Kaplan-Meier curves of univariate analysis data (log-rank test). (a and b) The overall survival (OS) (a) and disease-free survival (DFS)
(b) for the patients with high versus low URG4 expression. (c) The OS for the patients at stages Ib1-Ib2 with high versus low URG4 expression.
(d) The OS for the patients without lymph node metastasis with high versus low URG4 expression. (e) The OS for the patients with high versus
low URG4 expression who received concurrent chemotherapy and radiation therapy. (f) The OS for the patients with high versus low URG4 expression
who received radiation therapy.
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the prognosis of cervical cancer patients. Recently, a large
number of studies have identified certain genes associated
with cervical lymph node metastasis, including Sam68,
CRAM and EZH2 [7,14,15]. Because all of patients werein early stage in our study, the number of patients with
lymph node metastasis was small and they had a good
prognosis. It was failed to show lymph node metastases
was an independent prognostic factor for survival. We also
showed that URG4 expression was high in the lymph node
Table 4 Univariate and multivariate analyses of various prognostic parameters in the patients with cervical cancer Cox
regression analysis
Univariate analysis Multivariate analysis*
No. patients p Regression coefficient (SE) P Relative risk 95% confidence interval
URG4 2.755 (0.782) <0.0001
Low expression 108 <0.0001 Ref
High expression 59 <0.0001 21.645 4.516-103.743
Deep stromal invasion 0.034
Yes 100 0.264 Ref
No 67 0.034 0.282 0.087-0.914
*The factors in multivariate analysis included Age, Squamous cell carcinoma antigen, FIGO stage, Tumor size, Histological type, Histological differentiation, Deep
stromal invasion, Lymphovascular space involvement, Positive parametrium, Positive surgical margin, Vaginal involvement, N classification, M classification,
Concurrent chemotherapy and Radiotherapy, Radiotherapy and Expression of URG4.
(The endpoint is OS).
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lated with lymph node metastasis. In a more detailed
survival study, we observed a significant correlation
between shorter OS and high URG4 expression in the
“without lymph node metastasis” subgroup. This suggests
that URG4 may be a useful prognostic marker for cervical
cancer patients without lymph node metastasis. URG4
is regulated by the Akt-mediated phosphorylation of
FOXO3a, which stimulates the cell cycle [8] or alters
cyclin D1 levels by circumventing a cell cycle checkpoint
(G1 to S phase) [9]. It is well known that Akt plays a role
in tumour-induced lymphangiogenesis in colorectal car-
cinoma [16]. In the case of lymph node metastasis, we
hypothesise that URG4 may regulate the expression of
VEGF-C though the Akt signalling pathway by mediating
lymphangiogenesis in cervical cancer cells. Further func-
tional studies are needed to verify these findings to establish
URG4 as a prognostic marker in cervical cancer and to
clarify its role in carcinogenesis and progression.
For patients with lymph node metastasis, further treat-
ments are required. To date, radical hysterectomy plus
lymphadenectomy or chemoradiation have been the stand-
ard treatments for early-stage cervical cancer patients
[17,18]. A prospective, randomised clinical trial has shown
that concurrent chemotherapy and radiotherapy improves
the survival time of early-stage cervical cancer patients
with high-risk prognostic factors compared with RT alone
[19]. In our study, the patients with any of the “high-risk”
prognostic factors, including pelvic lymph node metastasis,
positive parametrial involvement, positive surgical margin,
deep stromal invasion and large tumor size (over 4 cm), re-
ceived chemotherapy and radiotherapy. The patients who
were only with lymph vascular space invasion or vaginal
involvement received RT. However, those who refused
concurrent chemotherapy were treated with RT alone.
We found that higher URG4 expression was correlated
with a significantly shorter OS in the concurrent chemother-
apy and radiotherapy subgroup. However, no correlationwas observed in the subgroup receiving only radiotherapy.
This indicates that URG4 expression is a more signifi-
cant predictor of the prognosis of early-stage cervical
cancer patients who require concurrent chemotherapy
and radiotherapy.
Recently, a number of studies have focused on targeted
drugs for the treatment of cervical cancer. Tewari et al.
have found that chemotherapy combined with bevacizumab
improves OS in recurrent, persistent or metastatic cervical
cancer patients [20]. Nogueira et al. have revealed that
EGFR inhibitors combined with chemoradiation result
in high levels of complete remission in patients with lo-
cally advanced cervical cancer [21]. Consistent with the
above findings, our study exploring URG4 as a target of
cervical cancer has shown extremely promising results
that may be of future clinical value.
Conclusions
In conclusion, this is the first study to assess the expression
and clinical significance of URG4 in early-stage cervical
cancer. URG4 could represent a prognostic biomarker and
therapeutic target for early-stage cervical cancer patients.
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analysis (log-rank test). (a) The OS for the patients with stages IIa1-IIa2
cervical cancer and high versus low URG4 expression. (b) The OS for the
patients with lymph node metastasis and high versus low URG4 expression.
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